Omega Teknika

Omega Teknika is an Irish pharmaceutical company that focused on the development of high-purity omega-3 fatty acid products for the treatment of cardiovascular diseases. The company is most notable for its role in the development of icosapent ethyl, a purified ethyl ester of eicosapentaenoic acid (EPA). In 2004, Omega Teknika was acquired by Amarin Corporation, which utilized the company's intellectual property and research to launch the blockbuster drug Vascepa. The acquisition was a strategic move that shifted Amarin's focus from neurology to cardiovascular health. Today, Omega Teknika remains a key legal subsidiary within Amarin's corporate structure, supporting its global operations in lipid science. The company's legacy is defined by its contribution to the management of hypertriglyceridemia and the reduction of residual cardiovascular risk.